US 5698518A
· Carson et al.
· 1997
[cited by applicant]
US 20060008891A1
· Wang et al.
· 2006
[cited by applicant]
US 20060019256A1
· Clarke et al.
· 2006
[cited by applicant]
US 20060045881A1
· Modrem
· 2006
[cited by applicant]
US 20060177880A1
· Tacke et al.
· 2006
[cited by applicant]
US 20110151490A1
· Hillman et al.
· 2011
[cited by applicant]
JP 2004123679
· 2004
[cited by applicant]
JP 2006500944
· 2006
[cited by applicant]
WO WO1992002617
· 1992
[cited by applicant]
WO WO03083084A2
· 2003
[cited by examiner]
WO WO2004031409
· 2004
[cited by applicant]
WO WO2016125330
· 2016
[cited by applicant]
Marcus E Peter (2014) DICE, Cell Cycle, 13:9, 1373-1378. (Year: 2014).
[cited by examiner]
C. Lee Ventola (2017), P&T, vol. 42 No. 8, pp. 514-521. (Year: 2014).
[cited by examiner]
The Jackson Laboratory, Say goodbye to one size fits all cancer treatments, pp. 1-3,. (Year: 2018).
[cited by examiner]
Uniprot, P00772 CELA1_PIG, 99. 1-7, retrieved from https://www.uniprot.org/uniprotkb/P00772/entry, accessed on Sep. 19, 2025. (Year: 2025).
[cited by examiner]
Extended European Search Report issued in Corresponding European Application No. 18817894.1, dated Feb. 5, 2021.
[cited by applicant]
Ho et al., “Neutrophil elastase as a diagnostic marker and therapeutic target in colorectal cancers”
[cited by applicant]
Albrethsen et al., “Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study”
[cited by applicant]
Cao et al., “Potential roles of eosinophils in cancer therapy: epidemiological studies, experimental models, and clinical pathology”
[cited by applicant]
Chang et al., “TNF-alpha mediates eosinophil cationic protein-induced apoptosis in BEAS-2B cells”
[cited by applicant]
Chen et al., “CD95 promotes tumour growth”
[cited by applicant]
Coffelt et al., “Neutrophils in cancer: neutral no more”
[cited by applicant]
De Lima et al., “Effect of eosinophil cationic protein on human oral squamous carcinoma cell viability”
[cited by applicant]
Eruslanov et al., “Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer”
[cited by applicant]
Fox et al., “Neutrophil Apoptosis: Relevance to the Innate Immune Response and Inflammatory Disease”
[cited by applicant]
Hadji et al., “Death Induced by CD95 or CD95 Ligand Elimination”
[cited by applicant]
Holterman et al., “Overexpression of alpha-defensin is associated with bladder cancer invasiveness”
[cited by applicant]
Hunt et al., “Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer”
[cited by applicant]
International Search Report and Written Opinion in corresponding application No. PCT/US2018/037800, dated Jun. 15, 2018.
[cited by applicant]
Kopolovic et al., “A systematic review of transfusion-associated graft-versus-host disease”
[cited by applicant]
Loison et al., “Proteinase 3-dependent caspase-3 cleavage modulates neutrophil death and inflammation”
[cited by applicant]
Martin-Villalba et al., “CD95 in cancer: tool or target?”
[cited by applicant]
Mishalian et al., “Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression.”
[cited by applicant]
Murmann et al., “Induction of DISE in ovarian cancer cells in vivo”
[cited by applicant]
Peter, “DICE: A novel tumor surveillance mechanism—a new therapy for cancer?”
[cited by applicant]
Putzbach et al., “Many si/shRNAs can kill cancer cells by targeting multiple survival genes through an off-target mechanism”
[cited by applicant]
Qi et al., “Role of annexin A6 in cancer” Oncol Lett. 2015, 10(4), 1947-1952.
[cited by applicant]
Sato et al., “Neutrophil elastase and cancer”
[cited by applicant]
Vilá de Muga et al., “Annexin A6 inhibits Ras signalling in breast cancer cells”
[cited by applicant]
Wada et al., “Neutrophil elastase induces cell proliferation and migration by the release of TGF-alpha, PDGF and VEGF in esophageal cell lines”
[cited by applicant]
Wada et al., “Sivelestat, a specific neutrophil elastase inhibitor, suppresses the growth of gastric carcinoma cells by preventing the release of transforming growth factor-alpha”
[cited by applicant]
Wang et al., “Annexin A6 is down-regulated through promoter methylation in gastric cancer”
[cited by applicant]
Winter et al., “Human Defensins: Potential Tools for Clinical Applications”
[cited by applicant]
Xu et al., “Human alpha-defensin-1 inhibits growth of human lung adenocarcinoma xenograft in nude mice”
[cited by applicant]
Young et al., “Mechanism of membrane damage mediated by human eosinophil cationic protein”
[cited by applicant]
Zalewski et al., “Apoptosis-Regulatory Factors as Potential Drug Targets in the Epithelium of Normal and Inflamed Airways”
[cited by applicant]
Office Action issued in Corresponding Japanese Application No. 2019-569454, dated May 9, 2022 (English Translation provided).
[cited by applicant]
English translation of Office Communication issued in Japanese Patent Application No. 2022-192891, dated Jan. 30, 2024.
[cited by applicant]